ABSTRACT:
Velpatasvir is a directly acting anti-viral medication used for the inhibition of hepatitis C virus. Sofosbuvir is a directly acting anti-viral medication used for the treatment of chronic hepatitis C virus infection. The combination of Sofosbuvir and Velpatasvir works by stopping the hepatitis C virus from spreading inside the body. A new liquid chromatographic method has been developed for the simultaneous determination of Sofosbuvir and Velpatasvir in oral dosage forms. Shimadzu Model CBM-20A/20 Alite UFLC system with PDA detector and Zorbox C18 column were used for the chromatographic study. Mobile phase mixture consisting of 0.1% Acetic acid: Acetonitrile (35:65) with a flow rate 1.0ml/min was chosen for the simultaneous determination of Sofosbuvir and Velpatasvir (Detection wavelength 260nm). Linearity was observed over the concentration range 4.0-400µg/ml and 1.0-100µg/ml with regression equations y = 30222x + 1253.9 (R² = 0.9999) and y = 38962x +292.37 (R² = 0.9999) for Sofosbuvir and Velpatasvir respectively. The combination of Sofosbuvir and Velpatasvir was subjected to forced degradation conditions and the method was validated as per ICH guidelines.
Cite this article:
Asia, Revu Baby Nalanda. Development and Validation of a New Stability Indicating RP-UFLC Method for the Simultaneous Estimation of Velpatasvir and Sofosbuvir in Pharmaceutical Formulations. Research Journal Pharmacy and Technology. 2025;18(8):3517-4. doi: 10.52711/0974-360X.2025.00506
Cite(Electronic):
Asia, Revu Baby Nalanda. Development and Validation of a New Stability Indicating RP-UFLC Method for the Simultaneous Estimation of Velpatasvir and Sofosbuvir in Pharmaceutical Formulations. Research Journal Pharmacy and Technology. 2025;18(8):3517-4. doi: 10.52711/0974-360X.2025.00506 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-9
REFERENCES:
1. Bhatia HK, Singh H, Grewal N, Natt NK. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. Journal of Pharmacology and Pharmaco Therapeutics. 2014; 5(4): 278-284.
2. Eric J Lawitz, Hadas Dvory-Sobol , Brian P Doehle, Angela S Worth, John McNally, Diana M Brainard, John O Link, Michael D Miller and Hongmei Mo. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016; 60(9): 5368-5378.
3. Yasir Mehmood, Ikram Ullah Khan, Yasser Shahzad, Syed Haroon Khalid, Muhammad Irfan, Sajid Asghar, Abid Mehmood Yousaf, Talib Hussain and Ikrima Khalid. Development and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of Sofosbuvir and Velpatasvir in fixed dose combination tablets and plasma. Pak J Pharm Sci. 2019; 32(4) (Supplementary): 1835-1842.
4. Sarath Nalla and Seshagiri Rao JVLN. A stability indicating RP-HPLC method for simultaneous estimation of Velpatasvir and Sofosbuvir in combined tablet dosage forms. World Journal of Pharmacy and Pharmaceutical Sciences. 2017; 6 (9): 1596-1611.
5. Jyothi U and Umadevi P. Analytical method development and validation for the simultaneous estimation of Sofosbuvir and Velpatasvir drug product by RP-HPLC method. Indo American Journal of Pharmaceutical Research. 2017; 7(8): 401-409.
6. Sandya Rani J and Devanna N. A new RP-HPLC method development and validation for simultaneous estimation of Sofosbuvir and Velpatasvir in pharmaceutical dosage form. International Journal of Engineering Technology Science and Research. 2017; 4(11): 145-152.
7. Padmavathi S, Sravanthi G, Sai srilakshmi G, Naga Varalakshmi T and Vani T. RP-HPLC method development and validation for the simultaneous estimation of Sofosbuvir and Velpatasvir in bulk and pharmaceutical dosage form. International Journal of Current Advanced Research. 2018; 7(6J): 13750-13756.
8. Priyanka K, Vinutha K, Sridevi P, Ramya B and Bhagavan Raju M. A Stability Indicating RP-HPLC method for simultaneous estimation of Velpatasvir and Sofosbuvir in its bulk and tablet dosage form. American Journal of Pharmtech Research. 2018; 8(2): 129-139.
9. Bhavyasri K, Samreen Begum, Aishwarya B, Sumakanth M. Method Development and Validation of Velpatasvir and Sofosbuvir by RP-HPLC. International Journal Pharmaceutical Sciences Reviews and Research. 2023; Article No. 01, 80(1): 1-6.
10. Chinababu D. A novel stress indicating RP-HPLC method development and validation for the simultaneous estimation of Velpatasvir and Sofosbuvir in bulk and its tablet dosage form. Journal of Pharmaceutical Research International. 2019; 26(2): 1-10.
11. Hemchand S, Ravi Chandra Babu R and Mathrusri Annapurna M. New stability indicating RP-UFLC method for the simultaneous determination of Velpatasvir and Sofosbuvir in tablets. Research Journal of Pharmacy and Technology. 2018; 11(12): 5637-5642.
12. Geetha Susmita A and G Rajitha G. Development and validation of stability indicating UPLC method for simultaneous estimation of Sofosbuvir and Velpatasvir in tablet dosage form. International Journal of Pharmaceutical Sciences and Research. 2018; 9(11): 4764-4769.
13. ICH Stability testing of new drug substances and products Q1A (R2), 2003.
14. ICH Validation of analytical procedures: Text and Methodology Q2(R1), 2005.